Simulations Plus, Inc. (NASDAQ:SLP – Free Report) – Investment analysts at William Blair reduced their Q1 2026 earnings estimates for shares of Simulations Plus in a research report issued to clients and investors on Monday, January 27th. William Blair analyst M. Smock now forecasts that the technology company will post earnings of $0.16 per share for the quarter, down from their previous forecast of $0.17. William Blair has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q2 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.41 EPS and FY2026 earnings at $1.32 EPS.
Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Stephens started coverage on shares of Simulations Plus in a research report on Friday, November 15th. They set an “overweight” rating and a $39.00 target price on the stock. Finally, BTIG Research cut their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.40.
Simulations Plus Stock Performance
SLP opened at $34.27 on Wednesday. The firm’s 50-day simple moving average is $30.31 and its 200-day simple moving average is $32.70. Simulations Plus has a twelve month low of $24.00 and a twelve month high of $51.22. The firm has a market cap of $688.48 million, a price-to-earnings ratio of 85.68 and a beta of 0.80.
Insider Transactions at Simulations Plus
In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 19.40% of the company’s stock.
Hedge Funds Weigh In On Simulations Plus
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. boosted its position in Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after purchasing an additional 370 shares during the period. nVerses Capital LLC lifted its holdings in shares of Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after buying an additional 1,100 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Simulations Plus during the third quarter worth $59,000. US Bancorp DE lifted its holdings in shares of Simulations Plus by 37.0% during the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after buying an additional 1,343 shares in the last quarter. Finally, Pitcairn Co. lifted its holdings in shares of Simulations Plus by 9.1% during the third quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock worth $211,000 after buying an additional 549 shares in the last quarter. 78.08% of the stock is owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
See Also
- Five stocks we like better than Simulations Plus
- Best Aerospace Stocks Investing
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Stock Dividend Cuts Happen Are You Ready?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.